Journal of Pharmacy and Pharmacology · 2020 · 16 citations · 17 references
MedicineImmunologyOncologyCell SignalingGastrointestinal OncologyMolecular OncologyCancer BiomarkersCancer Cell SignalingCancer ImmunotherapyCytokines In Tumor ImmunityGastric CancerOncology PharmacologyAnticancer ActivityCancer Signaling PathwaysCell Viability AssaysEnzyme-linked Immunosorbent Assay (Elisa)Nf-kappa B-mediated Anti-apoptotic SignalingNuclear Factor Kappa B InhibitionNuclear Factor Kappa B SignalingViability Assays
OBJECTIVES: Britanin was explored for the antitumour effect on gastric cancer, which is a sesquiterpene lactone (SL) extracted from Inula japonica. METHODS: In the present study, cell viability assays were performed to evaluate the antiproliferation effect of Britanin on gastric cancer cells. Tumour development in BGC-823 cell-bearing nude mice was monitored in real-time after Britanin treatment via a bioluminescent imaging method. Western blotting analysis and enzyme-linked immunosorbent assays detected proteins associated with the nuclear factor (NF)-κB signalling pathway. KEY FINDINGS: Britanin can suppress the proliferation of gastric cancer cells in vitro and the growth of tumours in vivo. In the treatment group, decreased levels of p65 and phosphorylated (p)-p65 were observed. This indicated that NF-κB plays an important role in the antitumour effect of Britanin. Furthermore, considering the additional role of NF-κB in the immune system, the levels of the downstream molecules interleukin (IL)-2 and the cytokine IL-10 were subsequently determined in vivo. An increase in the IL-2 level and a decrease in the IL-10 level indicated that Britanin elicited an enhanced immune response. CONCLUSIONS: Britanin may be a promising candidate for gastric cancer chemotherapy, and its anticancer effect likely depends on an NF-κB-mediated immune response.
17
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Gastric Cancer · 2016 · 2.5K citations · Full text
Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · The Lancet · 2013 · 2.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung et al. · Journal of Clinical Oncology · 2014 · 624 citations · Full text
Medicine, Oncology, Pharmacology +15